Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?

被引：1
|
作者：
Saydan, Betuel [1 ]
Ozmen, Deniz [2 ]
Eskazan, Ahmet Emre [2 ]
机构：
[1] Ankara Univ, Fac Med, Ankara, Turkiye
[2] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Internal Med, Div Hematol, Istanbul, Turkiye
来源：
EXPERT REVIEW OF HEMATOLOGY | 2024年 / 17卷 / 07期
关键词：
Chronic myeloid leukemia; CML; dasatinib; low-dose; 50; mg; CHRONIC LYMPHOCYTIC-LEUKEMIA; DECISION-SUPPORT-SYSTEM; SURVIVAL; CLL; INCORPORATE; PREFERENCES; POPULATION; GUIDELINES; IBRUTINIB; LYMPHOMA;
D O I：
10.1080/17474086.2024.2370556
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：275 / 277
页数：3
相关论文
共 50 条
  • [1] Early results of lower dose dasatinib (50mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia
    Naqvi, Kiran
    Jabbour, Elias
    Skinner, Jeffrey
    Yilmaz, Musa
    Ferrajoli, Alessandra
    Bose, Prithviraj
    Thompson, Philip
    Alvarado, Yesid
    Jain, Nitin
    Takahashi, Koichi
    Burger, Jan
    Estrov, Zeev
    Borthakur, Gautam
    Pemmaraju, Naveen
    Paul, Shilpa
    Cortes, Jorge
    Kantarjian, Hagop M.
    CANCER, 2018, 124 (13) : 2740 - 2747
  • [2] Low-Dose Dasatinib 50 mg Daily Versus Standard-Dose Dasatinib 100 mg Daily in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis
    Sasaki, Koji
    Jabbour, Elias
    Naqvi, Kiran
    Skinner, Jeffrey
    Anderson, Kristin
    Dellasala, Sara
    Yilmaz, Musa
    Ferrajoli, Alessandra
    Bose, Prithviraj
    Thompson, Philip
    Alvarado, Yesid
    Jain, Nitin
    Takahashi, Koichi
    Burger, Jan
    Estrov, Zeev
    Borthakur, Gautam
    Pemmaraju, Naveen
    Paul, Shilpa
    Pierce, Sherry
    Cortes, Jorge
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S237 - S237
  • [3] Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia
    Naqvi, Kiran
    Jabbour, Elias
    Skinner, Jeffrey
    Anderson, Kristin
    Dellasala, Sara
    Yilmaz, Musa
    Ferrajoli, Alessandra
    Bose, Prithviraj
    Thompson, Philip
    Alvarado, Yesid
    Jain, Nitin
    Takahashi, Koichi
    Burger, Jan
    Estrov, Zeev
    Borthakur, Gautam
    Pemmaraju, Naveen
    Paul, Shilpa
    Cortes, Jorge
    Kantarjian, Hagop M.
    CANCER, 2020, 126 (01) : 67 - 75
  • [4] Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia
    Yoji Ishida
    Kazunori Murai
    Kohei Yamaguchi
    Takuto Miyagishima
    Motohiro Shindo
    Kazuei Ogawa
    Takahiro Nagashima
    Shinji Sato
    Reiko Watanabe
    Satoshi Yamamoto
    Takayuki Hirose
    Souich Saitou
    Masakatsu Yonezumi
    Takeshi Kondo
    Yuichi Kato
    Noboru Mochizuki
    Keiko Ohno
    Satoshi Kishino
    Kohmei Kubo
    Tatsuo Oyake
    Shigeki Ito
    European Journal of Clinical Pharmacology, 2016, 72 : 185 - 193
  • [5] Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia
    Ishida, Yoji
    Murai, Kazunori
    Yamaguchi, Kohei
    Miyagishima, Takuto
    Shindo, Motohiro
    Ogawa, Kazuei
    Nagashima, Takahiro
    Sato, Shinji
    Watanabe, Reiko
    Yamamoto, Satoshi
    Hirose, Takayuki
    Saitou, Souich
    Yonezumi, Masakatsu
    Kondo, Takeshi
    Kato, Yuichi
    Mochizuki, Noboru
    Ohno, Keiko
    Kishino, Satoshi
    Kubo, Kohmei
    Oyake, Tatsuo
    Ito, Shigeki
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (02) : 185 - 193
  • [6] Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia
    Jabbour, Elias
    Haddad, Fadi G.
    Sasaki, Koji
    Carter, Bing Z.
    Alvarado, Yesid
    Nasnas, Cedric
    Nasr, Lewis
    Masarova, Lucia
    Daver, Naval
    Pemmaraju, Naveen
    Short, Nicholas J.
    Skinner, Jeffrey
    Kadia, Tapan
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Issa, Ghayas C.
    Andreeff, Michael
    Kantarjian, Hagop
    CANCER, 2024, 130 (15) : 2652 - 2659
  • [7] Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Abbott, Brian L.
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 272 - 281
  • [8] Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
    Kantarjian, Hagop
    Shah, Neil P.
    Hochhaus, Andreas
    Cortes, Jorge
    Shah, Sandip
    Ayala, Manuel
    Moiraghi, Beatriz
    Shen, Zhixiang
    Mayer, Jiri
    Pasquini, Ricardo
    Nakamae, Hirohisa
    Huguet, Francoise
    Boque, Concepcion
    Chuah, Charles
    Bleickardt, Eric
    Bradley-Garelik, M. Brigid
    Zhu, Chao
    Szatrowski, Ted
    Shapiro, David
    Baccarani, Michele
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24) : 2260 - 2270
  • [9] Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
    Massimo Breccia
    Giuliana Alimena
    BioDrugs, 2011, 25 : 147 - 157
  • [10] Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis
    Noriyoshi Iriyama
    Kei-Ji Sugimoto
    Eriko Sato
    Tomoiku Takaku
    Michihide Tokuhira
    Tomonori Nakazato
    Maho Ishikawa
    Hiroyuki Fujita
    Isao Fujioka
    Yuta Kimura
    Norio Asou
    Masahiro Kizaki
    Norio Komatsu
    Yoshihiro Hatta
    Tatsuya Kawaguchi
    Medical Oncology, 2018, 35
12345